10+ Top Supplement Trends in 2026 (Exclusive Wonnda Data)
Most supplement trend lists are built from consumer surveys and retail scan data. This one is built from the other side of the supply chain. Wonnda is a B2B sourcing platform where brands, retailers and private label teams post what they want manufactured, and the ranking below reflects what our category team sees most often in supplement sourcing requests and supplier searches through 2025 and into 2026.
That difference matters more than it sounds. Retail data tells you what sold last quarter. Sourcing demand tells you what will be on shelf in nine to eighteen months, because that is roughly how long it takes to get from a first brief to a first production run. What follows is the demand we see upstream, checked against published market data, ingredient science and the EU and US rules that decide whether a product can legally say what its marketing wants it to say.
Key Takeaways
Longevity, hydration and beauty from within are the three categories generating the most supplement sourcing requests on Wonnda in 2026.
GLP-1 companion products are the fastest-arriving new category. Gallup put current GLP-1 use at 11% of US adults in 2026, up from 3% in 2024.
Format is the constraint founders underestimate. Gummies cannot carry gram-scale doses, creatine degrades in water, and clinically dosed collagen does not fit in a chew.
Regulatory reality splits the EU and US sharply. NMN is lawful in US supplements and not yet authorised in the EU. Collagen has zero authorised EU health claims. The word "probiotic" is restricted on labels in most member states.
Typical private label MOQs run 5,000 to 25,000 units for capsules and stick packs with an existing formula, and 10,000 to 50,000 for gummies. Custom formulas needing stability testing push higher.
In almost every category, the compliant claim is carried by an added vitamin or mineral, not by the hero ingredient.
The 12 Supplement Trends of 2026 at a Glance
# | Trend | Format that works | Typical private label MOQ | Hardest part |
|---|---|---|---|---|
1 | Longevity | Capsules, softgels, gummies | 5,000 to 25,000 (stock formula) | Branded ingredient licensing, Novel Food status |
2 | Hydration and electrolytes | Stick packs, effervescent tablets | 5,000 to 20,000 | Taste masking, moisture control |
3 | Beauty from within | Powders, liquids, gummies | 5,000 to 50,000 | German case law on skin claims |
4 | GLP-1 companion | Protein powders, shots, capsules | 5,000 to 25,000 per SKU | Claim wording, altered taste perception |
5 | Functional mushrooms | Capsules, powders, coffee | 5,000 to 25,000 | Extract quality, EU Novel Food status |
6 | Functional gummies | Gummies, daily sachets | 5,000 to 50,000 per flavour | Overages, stability, 18-month shelf life |
7 | Creatine | Powder, chews with caution | 5,000 to 25,000 | Raw material supply, degradation in water |
8 | Collagen | Powders, sachets, liquid shots | 5,000 to 25,000 | Dose economics, no authorised EU claim |
9 | Ashwagandha | Capsules, stacks | 5,000 to 25,000 | Leaf adulteration, national restrictions |
10 | Gut health | Capsules, sachets, liquids | 5,000 to 25,000 | Real-time stability, label terminology |
11 | Oral care | Lozenges, mints, chewables | 5,000 to 25,000 | Licensed strains, viability after compression |
12 | Protein | Powders, RTD, bars | 5,000 to 20,000 (sachets) | Whey price volatility, heavy metals |
1. Longevity Supplements
Longevity is the single most requested supplement brief we handle. It is also the one where the gap between marketing ambition and regulatory permission is widest. Nutrition Business Journal put healthy aging as the fastest-growing US health focus area in 2025 at 14.3% growth, ahead of weight management and gut health.
The ingredients that carry real human data are urolithin A (branded as Mitopure, dosed at 500 mg/day), nicotinamide riboside, spermidine from wheat germ, trans-resveratrol and NMN. The EU has authorised nicotinamide riboside at a maximum of 300 mg/day, spermidine at 6 mg/day and trans-resveratrol at 150 mg/day for adults. NMN is the interesting case: the FDA confirmed in September 2025 that it is not excluded from the dietary supplement definition, so it is lawful in the US, while EFSA only issued a positive safety opinion in 2026 and EU authorisation is still pending. Taurine, which drove a wave of 2023 launches, lost most of its longevity rationale when a 2025 Science paper found taurine levels rise rather than fall with age.
Brands worth studying: Timeline (Switzerland) for the science-first model, Longevity Labs+ with spermidineLIFE (Austria) for the pharmacy channel route, and NOVOS and Avea Life for direct-to-consumer stacks. The commercial catch is that urolithin A and nicotinamide riboside are patent-protected, so a serious longevity launch is often an ingredient licensing negotiation before it is a manufacturing one.
2. Hydration Supplements and Electrolytes
Hydration is the most accessible category on this list for a first-time brand. Grand View Research sizes the electrolyte powder market at USD 6.6 billion in 2025 growing to USD 12.9 billion by 2033, with single-serve packaging holding 65.3% share and growing fastest. In Europe, waterdrop closed a funding round above EUR 100 million in May 2026 at roughly EUR 150 million annual revenue, which is the clearest signal yet that functional hydration is an institutionally backable category here, not just a US phenomenon.
There is no consensus formulation. LMNT runs 1,000 mg sodium per stick, Ultima Replenisher runs 55 mg. The category has split into high-sodium performance and low-sodium wellness, and the crowded ground is the 300 to 500 mg middle. Use magnesium malate, citrate or glycinate rather than oxide, and expect several rounds of flavour work: 1,000 mg of sodium is aggressively salty and magnesium is bitter.
The EU trap is specific and catches almost everyone. Regulation 432/2012 authorises the carbohydrate-electrolyte hydration claims only for solutions containing 80 to 350 kcal/L from carbohydrate. A zero-sugar electrolyte product cannot legally make either claim in the EU. The workable route is "magnesium contributes to electrolyte balance", which requires the product to be a source of magnesium.
3. Beauty From Within
Ingestible beauty keeps growing, with MarketsandMarkets putting beauty supplements at USD 3.96 billion in 2025 heading to USD 5.76 billion by 2030. The formats are moving from capsules to liquids, shots and sparkling drinks, which changes which manufacturer you need.
On ingredients, the branded bioactive collagen peptides carry the trial data. Verisol at 2.5 g/day is the most replicated skin dose. Oral hyaluronic acid has accumulating support around 120 to 240 mg/day. Astaxanthin is capped in the EU at 8 mg/day for adults and only the natural Haematococcus pluvialis source is authorised. "Vegan collagen" is not collagen; it is an amino acid and cofactor blend, and the peptide trial data does not transfer.
The compliance change nobody has priced in yet is the German Federal Court of Justice ruling of 9 October 2025 (I ZR 135/24, "Kollagen-Trinkampullen"). The court held that claims about skin moisture, elasticity and density are health claims judged by consumer perception, and rejected EFSA's own guidance that skin structure claims sit outside the Health Claims Regulation. Purely aesthetic language survived. The practical drafting rule for Germany, and increasingly the wider EU, is "healthy-looking skin" rather than "healthy skin". Look at Vida Glow, Bears with Benefits (Germany) and Cymbiotika for how differently this gets executed.
4. GLP-1 Companion Supplements
This is our addition to the list, and it is the fastest-arriving new brief we see. Gallup measured current GLP-1 use for weight loss at 11% of US adults in mid-2026, up from 8% in 2025 and 3% in 2024. The product logic is straightforward: roughly a quarter of the weight lost on these drugs is lean mass, appetite suppression makes micronutrient intake harder, and about 60% of lost weight is regained within a year of stopping.
Protein is the anchor, at 1.2 to 1.5 g per kg of body weight per day, distributed across meals. Around it sit creatine, leucine and EAAs, HMB, omega-3, low-viscosity soluble fibre and micronutrient repletion covering iron, B12, folate, vitamin D and calcium. Be honest about the evidence: a 2025 review in Metabolites states plainly that direct randomised evidence on protein supplementation during GLP-1 therapy does not yet exist.
The Vitamin Shoppe launched the first mainstream retailer own-brand GLP-1 support line in March 2025 as five SKUs covering distinct need states, and Nestlé Health Science built a routing platform rather than new products. Celebrate Vitamins runs the clearest US and EU dual-market example. Two warnings: GLP-1 users report heightened sweetness sensitivity and amplified bitterness, so a formula that tests well with gym consumers can fail here, and in the EU a "GLP-1 friendly" claim is treated as a disease or health claim with no realistic route to authorisation. The UK ASA has already banned ads containing the term.
5. Functional Mushroom Supplements
Demand is real and the quality floor is low. SPINS data cited in January 2026 put US retail sales of functional mushroom supplements at USD 74.6 million, up 7.7%, with lion's mane the largest single species and reishi growing fastest at 22.5%. That figure almost certainly excludes Amazon and direct-to-consumer, where most of this category actually lives.
The sourcing question that decides everything is fruiting body versus mycelium grown on grain. Nammex testing using the Megazyme enzymatic method found fruiting bodies at 6.79% to 49.3% beta-glucans with starch under 3%, while commercial mycelium-on-grain samples ran 1% to 15.26% beta-glucans with 24% to 66% starch. Suppliers who report only "polysaccharides above 30%" are reporting grain. Ask for beta-glucan and alpha-glucan quantified separately, species-specific markers by HPLC, and a batch-current COA. Note that the Functional Mushroom Council, launched in January 2026, argues the opposite case for whole-lifecycle products, and both sides have commercial interests.
EU Novel Food status is the gate, and it turns on the form rather than the species. Shiitake mycelial extract is authorised on the Union list. Lion's mane, reishi and shiitake fruiting bodies are treated as not novel, but their dehydrated mycelium powders are novel. Cordyceps militaris is novel in all forms, while Cordyceps sinensis is treated as not novel in food supplements. Chaga is not novel in food supplements but is novel in beverages, which is exactly what catches mushroom coffee. There are no EFSA-authorised health claims for mushroom extracts. Hifas da Terra (Spain) is the best European example of turning that regulatory rigour into a moat.
6. Functional Gummies
Gummies are no longer a format, they are a category. Mordor Intelligence sizes global gummy supplements at USD 27.71 billion in 2026 growing to USD 40.06 billion by 2031. The commercial argument is conversion: O Positiv Health reported a 20% conversion rate lift after adding a gummy version of an existing product, and Grüns reached roughly USD 300 million annualised revenue within 24 months of launch.
The physics are less friendly. Gelatin holds about 67.5% of the market and forgives processing mistakes because it can be remelted. Pectin is vegan, halal and kosher compatible and growing fastest, but a failed pectin batch is scrapped, so pH, calcium and thermal history control have to be tight. Manufacturers add 20% to 50% excess active to hold label claim through shelf life, and USP has proposed overages of 145% to 150% for folic acid and vitamin C in gummies. On an expensive active, that overage is what destroys the unit economics. Shelf life runs about 18 months against 24 or more for capsules.
Two EU specifics: titanium dioxide (E171) is banned as a food additive, so coatings and opacifiers need reformulating, and maximum vitamin and mineral levels are still not harmonised across member states, so one formula can be compliant in Italy and not in Germany. Bears with Benefits (Germany) and Novomins (UK) are the European reference points. Budget MOQ per flavour, not per SKU.
7. Creatine Supplements
Creatine has broken out of sports nutrition. Alzchem reported US creatine sales up 60.6% over the past year, SPINS tracks the category at 17.2% CAGR, and search data shows around 253,000 monthly US searches for creatine, up 155.5% year on year, with "creatine for women" and "creatine for females" at roughly 110,000 each. The buyer profile that surprised everyone is women aged 40 to 65, with most of the surrounding discussion tied to menopause and perimenopause.
Creatine also has something almost nothing else on this list has: two authorised EU health claims. Regulation 432/2012 permits the physical performance claim at 3 g/day, and Regulation 2017/672 permits a muscle strength claim for adults over 55 combined with resistance training. EFSA rejected the cognition claim in November 2024, which means the brain fog and menopause cognition angle driving consumer demand cannot be used in EU marketing.
Format is where launches fail. Creatine cyclises to inert creatinine in water, faster at low pH and high heat. Independent testing has been brutal: NOW Foods found only 6 of 12 creatine gummies contained the claimed amount, and SuppCo found 5 of 5 powders passed while only 2 of 6 gummies did. Glanbia's encapsulated CreaBev retained 73% at pH 7.0 after 12 months and just 30% at the pH 2.8 typical of a soft drink. A class action was filed against Create Wellness in April 2026 over gummy potency, which tells you the live legal risk is label accuracy, not safety. On supply, Alzchem is investing EUR 120 million in a German plant that comes online in late 2027, and Creapure-grade material carries a 30 to 40 cent per dose premium over Chinese material. Specify limits for dicyandiamide, dihydrotriazine and creatinine on your COA.
8. Collagen
Collagen is mature, still growing, and structurally European. Grand View Research puts collagen peptides at USD 2.53 billion in 2024 heading to USD 4.90 billion by 2030, and Europe is the largest region for collagen overall at 35.3% share, with marine the fastest-growing source at 11.9%.
The commercial insight most founders miss is that collagen is not one ingredient. Branded bioactive peptides work at 2.5 g and carry the published trials. Generic hydrolysate is sold at 10 g and borrows their halo. That is a fourfold difference in cost of goods per serving and a completely different pack format. Bovine hide yields types I and III, marine is predominantly type I, chicken sternum is the type II joint source, and undenatured UC-II works through a different mechanism at a far smaller dose.
On claims, EFSA rejected the joint health claim in 2011 and Gelita's Verisol skin claim in 2013. There are no authorised EU health claims for collagen at all. Combined with the October 2025 German ruling covered under beauty from within, this is the most claim-constrained major category on the list. Note the format ceiling too: you cannot fit a clinical collagen dose into a gummy or a capsule, which is why powders, sachets and liquid ampoules own the credible end. ELASTEN (Germany) is the archetype for the pharmacy ampoule model, Ancient + Brave (UK) for EU sourcing as a differentiator.
9. Ashwagandha
Ashwagandha remains one of the highest-volume botanical briefs we see, at a steady high single digit growth rate rather than a breakout one. Grand View Research puts it at USD 777.8 million in 2025 heading to about USD 1.53 billion by 2033. Retail pharmacy accounts for roughly 47% of the channel, which tells you how medicalised the positioning has become in Europe.
It is also the highest regulatory risk category on this list. Denmark banned ashwagandha in food supplements in 2023 and notified other member states through RASFF. The Netherlands issued an advisory against use in 2024. France's ANSES issued population-specific warnings. The EU Heads of Food Safety Agencies proposed restricting it and eleven other botanicals under Article 8 in June 2024, though that procedure has not been formally initiated and EFSA has completed no formal safety assessment. Poland permits it with hard limits: a maximum of 3 g root powder and 10 mg withanolides per daily portion. A standard 600 mg dose at 5% withanolides delivers 30 mg, which is three times the Polish ceiling. A single pan-EU SKU is not currently realistic.
On sourcing, the defining problem is leaf adulteration and it is economically driven. At India's Neemuch wholesale market, leaf arrivals now exceed root by volume while selling at a fraction of root price. Because withaferin A is up to 20 times more concentrated in leaf, leaf-adulterated batches score higher on standard withanolide assays. A strong COA is not proof of authenticity. The BAPP laboratory guidance of October 2025 recommends HPTLC fingerprinting plus a limit test for flavonol glycosides, which appear in aerial parts but not root. Write that into your supplier agreement. Sunday Natural and ESN (both Germany) show the KSM-66 root-only route.
10. Gut Health: Probiotics, Prebiotics and Fibre
Gut health is a permanent fixture rather than a trend, and Innova ranked its "Gut Health Hub" theme second among 2026 food and beverage trends, with 59% of global consumers calling gut health very important. Grand View Research sizes the European gut health supplements market at USD 4.70 billion in 2025 heading to USD 8.15 billion by 2033, with postbiotics the fastest-growing product segment in Europe.
Strain selection beats CFU count. Lactobacillus rhamnosus GG is the most clinically documented single strain. Bacillus coagulans BC30 is spore-forming, so it survives heat processing and shelf-stable formats, and has documented data on increasing blood amino acid concentrations alongside milk protein, which makes it the obvious bridge into protein products. Chicory inulin holds a genuine authorised EFSA claim for normal defecation. Akkermansia is tightly controlled in the EU: only the pasteurised form is authorised, at a maximum 3.4 x 10¹⁰ cells/day for adults, and A-Mansia Biotech holds data protection until 1 March 2027, so there is effectively one EU supply route.
The label problem is the one to plan around. The European Commission treats "probiotic" as an unauthorised health claim, and more than 400 probiotic claim applications have been submitted without a single authorisation for supplements. Roughly eleven member states allow the term through national derogations, with different conditions. Italy requires at least 10⁹ live cells per day maintained to end of shelf life, France requires 10⁷ to 10⁹ per strain per day. Either use "live cultures" as the pan-EU safe descriptor or budget for country-specific artwork. One production note: accelerated stability testing is invalid for probiotics because heat destroys viability, so you need real-time data and cannot validate a genuinely new formula inside a six-month launch window. Seed, Symprove (acquired by Metagenics in January 2026) and Optibac are the brands worth studying.
11. Oral Care Supplements
This is the smallest category on the list and the best risk-adjusted white space we see. Grand View Research puts oral microbiome products at roughly USD 1.5 billion in 2026 growing at 13.1% to USD 3.6 billion by 2033, which is the highest growth rate among these twelve trends. The branded competition is thin and dominated by ingredient houses and toothpaste incumbents rather than consumer brands.
The anchor strains are Streptococcus salivarius K12 and M18 from BLIS Technologies, commercialised through Probi. M18 targets S. mutans and plaque at a documented 1 billion CFU/day. K12 covers throat immunity and breath, with commercial lozenges running 1 to 2.5 billion CFU. BioGaia's Prodentis uses two L. reuteri strains. Lallemand's Oralis SB holds a Health Canada NPN with an approved plaque and S. mutans claim, which is the cleanest authorised claim precedent in the category and is not transferable to the EU. Xylitol does double duty as sweetener and active.
Format here is dictated by biology rather than fashion. The mechanism needs residence time in the mouth, so slow-dissolving lozenges, chewables and mints are correct and a swallowed capsule is functionally wrong. That is good news commercially: tablet-press economics mean 5,000 to 25,000 units and 6 to 10 weeks rather than gummy timelines, doses are low so ingredient cost per unit is modest, and no cold chain is needed. Two cautions. Compression kills viable cells, so ask for post-compression viability data rather than blend potency. And if you are considering nano-hydroxyapatite, note that the SCCS opinions govern cosmetics, not food: toothpaste and mouthwash sit under Regulation 2024/858 with a mandatory rod-shaped particle specification, while ingestible nHA in a swallowed supplement has no EU Novel Food authorisation we can find. Fygg (US) and Luvbiotics (UK) show the format working at small brand scale.
12. Protein
Innova ranked "Powerhouse Protein" the number one food and beverage trend for 2026, with around 60% of global consumers actively seeking more protein and 80% saying they pay attention to it. Grand View Research sizes protein supplements at USD 31.9 billion in 2026 growing to USD 63.2 billion by 2033, with powder at 48.8% share and ready-to-drink the fastest-growing form. The larger opportunity is fortified everyday food rather than tubs: bars, drinks, yogurt, coffee and soda.
Two hard constraints define a 2026 protein launch. The first is ingredient cost. WPC80 prices are reported up 108% over two years and WPI up 139%, standard whey has risen more than 50% since January 2026, and global dairy processing capacity is constrained through 2027. Do not model a whey P&L on 2023 input costs. The second is heavy metals. Consumer Reports found in October 2025 that more than two thirds of tested powders and shakes exceeded its 0.5 µg/day level of concern for lead in a single serving, with plant-based averaging around nine times the lead of dairy-based. The Clean Label Project's January 2025 study, which drew methodological criticism worth reading alongside it, found 77% of plant-based products exceeding limits against 28% of whey, and organic averaging higher lead than non-organic. Cadmium in pea and rice is an agronomic problem, so specify growing region and demand lot-level COAs on finished product.
On claims, the EU threshold is energy-based, not gram-based: "source of protein" needs 12% of energy from protein and "high protein" needs 20%. A bar with 20 g of protein can fail if it is also high in fat or sugar. In the US, protein %DV must be PDCAAS-corrected, which hits plant blends hardest and has already generated litigation. Barebells (Sweden), David (US) and Arla's protein beverage work show where the format frontier sits.
What EU Rules Actually Allow You to Say
The single most useful thing to understand before briefing a manufacturer is that in most of these categories, the hero ingredient cannot carry the claim. An added vitamin or mineral does.
Ingredient | EU authorised health claim? | What brands use instead |
|---|---|---|
Creatine | Yes, two claims at 3 g/day | Nothing needed for performance; cognition claims not permitted |
Chicory inulin | Yes, normal defecation | Direct use |
Collagen | No, rejected 2011 and 2013 | Vitamin C for normal collagen formation, biotin, zinc |
Probiotic strains | No, term restricted in most member states | "Live cultures", plus vitamin or mineral claims |
Mushroom extracts | No, claims on hold since 2012 | Added zinc or B vitamins |
Ashwagandha | No, plus national restrictions | Magnesium, vitamin B6, zinc in a stack |
Hyaluronic acid | No | Biotin, selenium, copper, iodine, vitamin C |
Zero-sugar electrolytes | No, fails the carbohydrate condition | Magnesium contributes to electrolyte balance |
If you are still choosing a category, the fastest route to a real quote is to describe the format, target dose and market rather than the trend name. Post your requirements and get matched with suitable manufacturers, and you will find out within days whether your dose fits your format.
Three Trends We Would Not Build a First SKU Around
Creatine gummies. The consumer demand is real, but independent testing keeps finding underdosed product and the first potency class action landed in April 2026. If you want creatine, sell powder and win on purity documentation.
Taurine as a longevity story. The 2023 research that created the category was substantially undermined by a 2025 Science paper finding taurine rises rather than falls with age.
A pan-EU ashwagandha SKU. Denmark is closed, Poland's withanolide ceiling sits well below the clinical dose, and Article 8 restriction remains on the table. Treat it as a country-by-country product.
How to Pressure-Test Any of These Trends Before You Commit
Check the dose fits the format. Gram-scale actives (protein, collagen, creatine, most fibres) do not fit a gummy or a capsule at a sane serving count.
Check Novel Food status per form, not per species. A fruiting body extract and a mycelium powder of the same mushroom can have opposite status in the EU.
Check who owns the claim. If your hero ingredient has no authorised claim, decide now which vitamin or mineral will carry it and at what inclusion level.
Check which test method proves quality. Beta-glucan separated from alpha-glucan for mushrooms, HPTLC plus flavonol glycosides for ashwagandha, amino acid profiling rather than nitrogen for protein, post-compression viability for oral care.
Check the stability timeline against your launch date. Probiotics need real-time data. Gummies need accelerated and real-time. Neither compresses.
Check MOQ per flavour and per SKU. A five-SKU need-state range multiplies your minimum cash commitment by five.
Frequently asked
What is the biggest supplement trend of 2026?
Longevity supplements generate the most sourcing requests on Wonnda in 2026. Nutrition Business Journal also recorded healthy aging as the fastest-growing US health focus area in 2025 at 14.3% growth. The fastest-arriving newer category is GLP-1 companion products, driven by GLP-1 use reaching 11% of US adults.
What is the minimum order quantity for private label supplements?
What is the minimum order quantity for private label supplements?
How long does it take to launch a private label supplement?
Plan 8 to 16 weeks for a standard product and 20 weeks or more for complex or certified ones. Hard capsules run 6 to 10 weeks, softgels 12 to 18, gummies 14 to 20. Add 2 to 4 weeks for NSF or Informed Sport certification and build separate buffer for packaging lead times.
Which supplement trends have the hardest regulatory barriers in Europe?
Ashwagandha, functional mushrooms and GLP-1 companion products. Ashwagandha is banned in Denmark and restricted elsewhere. Most mushroom forms other than fruiting body extracts require Novel Food authorisation, and none carry an authorised health claim. A "GLP-1 friendly" claim is treated as a disease or health claim with no realistic route to authorisation in the EU.
